OGYGIA
Live / Allowed — Notice of allowance issued (as of 10 Mar 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 24 Jul 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99301669
- Mark type
- Stylized text
- Filed
- 24 Jul 2025
- Published for opposition
- 13 Jan 2026
- Attorney of record
- Jayme M Torelli
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for the central nervous system; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for the treatment of bipolar disorder; Pharmaceutical preparations for the treatment of schizophrenia; Pharmaceutical preparations for the treatment of bile acid diarrhea; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of tyrosine kinase inhibitor (TKI)-induced diarrhea; Pharmaceutical preparations for the treatment of COVID-19; Pharmaceutical preparations for the treatment of inflammatory lung injury (ILI); Pharmaceutical preparations for the treatment of acute respiratory distress syndrome (ARDS); Pharmaceutical preparations for the treatment of social anxiety disorder; Pharmaceutical preparations for the treatment of performance anxiety; Pharmaceutical preparations for the treatment of public speaking anxiety; Pharmaceutical preparations for the treatment of circadian rhythm disorders; Pharmaceutical preparations for the treatment of jet lag disorder; Pharmaceutical preparations for the treatment of insomnia; Pharmaceutical preparations for the treatment of Delayed Sleep Phase Disorder (DSPD); Pharmaceutical preparations for the treatment of Smith-Magenis Syndome; Pharmaceutical preparations for the treatment of nighttime sleep disturbances in patients with Smith-Magenis Syndrome (SMS); Pharmaceutical preparations for the treatment of major depressive disorder (MDD); Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of multiple myeloma; Pharmaceutical preparations for the treatment of Charcot-Marie-Tooth disease; Pharmaceutical preparations for the treatment of hematologic malignancies; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of cravings for opioid substances or opiate substances; Pharmaceutical preparations for the treatment and prevention of nausea; Pharmaceutical preparations for the treatment and prevention of vomiting; Pharmaceutical preparations for the treatment and prevention of substance dependence; Pharmaceutical preparations for the treatment and prevention of anxiety; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by an over-expression of the neuropeptide known as substance P; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by overstimulation of the neurokinin-1 (NK-1) receptor; Pharmaceutical preparations for the treatment of non-24 hour sleep-wake disorder (non-24)
Owner
- Vanda Pharmaceuticals Inc., Washington, DC, US
- Vanda Pharmaceuticals Inc., Washington, DC, US
Prosecution history
- 10 Mar 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 13 Jan 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 13 Jan 2026 — PUBLISHED FOR OPPOSITION
- 07 Jan 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 15 Dec 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 10 Dec 2025 — ASSIGNED TO EXAMINER
- 24 Jul 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 24 Jul 2025 — APPLICATION FILING RECEIPT MAILED
- 24 Jul 2025 — NEW APPLICATION ENTERED